轻度认知障碍中的结构和功能变化 在帕金森病中的轻度认知障碍中
Halil Güllüoğlu1, Duygu Hünerli2, Raif Çakmur3
1Department of Neurology, Izmir Ekonomi University Medical Point Hospital, Izmir 35080, Turkey.
Medicina (Kaunas, Lithuania)
|January 23, 2024
概括
白质体积损失在轻度认知障碍 (PD-MCI) 的帕金森病中比灰质体积损失更为明显. 神经心理测试损伤与PD-MCI患者的大脑体积减少相关.
科学领域:
- 神经学 神经学
- 神经成像是一种神经成像.
- 认知科学 认知科学
背景情况:
- 帕金森病中轻度认知障碍 (PD-MCI) 的确切原因尚不清楚.
- 早期的PD-MCI可能涉及特定的大脑区域的体积损失,如头,头顶和额叶皮层,以及海马缩.
- 了解这些变化对于早期诊断和干预至关重要.
研究的目的:
- 调查灰色和白质量与PD-MCI患者神经心理测试表现之间的相关性.
- 利用体积磁共振成像 (MRI) 来评估PD-MCI中的大脑结构.
- 探索神经成像发现与认知缺陷之间的关系.
主要方法:
- 一项涉及26名PD-MCI患者和26名健康老年人对照 (HC) 的比较研究.
- 卷积磁共振成像 (MRI) 用于测量灰质体积 (GMV) 和白质体积 (WMV).
- 进行了一系列神经心理测试,以评估认知功能.
主要成果:
- 患有PD-MCI的患者在几个神经心理测试中表现出受损的分数,包括迷你精神状态检查,步道制作测试A部分,时钟绘图测试,本顿线判断方向测试和五角形图像复制.
- 这些认知缺陷与PD-MCI患者的大脑体积减少有关.
- 与局部灰质体积 (GMV) 损失相比,在PD-MCI患者中观察到白质体积 (WMV) 的更显著下降.
结论:
- 白质量减少是PD-MCI的一个突出特征,可能比局部灰质量减少更为突出.
- 在PD-MCI患者的特定神经心理测试中表现下降可能是痴呆症进展的早期指标.
- 这些发现凸显了整合神经成像和神经心理评估来监测PD-MCI进展的潜力.
相关概念视频
01:15Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551
01:24Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
01:26Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:30Cognitive Development During Adulthood
112
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
112
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126